Northwire Canada EditionTuesday, July 14, 2026
Sign inSubscribe
Northwire
⌕
TLO 5.89 +10.9% ADE 0.135 +0.0% FAIR 0.055 +22.2% SVRS 0.425 −1.2% RES 0.035 +0.0% CYG 0.120 +0.0% MGG 0.315 −4.5% BUFF 0.770 +2.7% TKO 11.15 +11.9% MINK 0.100 −4.8% LCE 0.250 +0.0% AEF 0.160 +0.0% BEM 0.095 +5.6% APMI 0.120 +0.0% LIO 0.135 +3.9% TLO 5.89 +10.9% ADE 0.135 +0.0% FAIR 0.055 +22.2% SVRS 0.425 −1.2% RES 0.035 +0.0% CYG 0.120 +0.0% MGG 0.315 −4.5% BUFF 0.770 +2.7% TKO 11.15 +11.9% MINK 0.100 −4.8% LCE 0.250 +0.0% AEF 0.160 +0.0% BEM 0.095 +5.6% APMI 0.120 +0.0% LIO 0.135 +3.9%
Other

FutureGen Industries Provides Investment Performance Update and Shares Realized Gains

By The Northwire Desk — AI Analysis Mar 01, 2026 · 21:00 ONCO · 0.7 ONCO-INNOVATIONS LIMITED
ONCO · Price

Executive Summary

  • FutureGen Industries reported realized gains of $1,050,793.69 from the sale of shares in three portfolio companies during 2025.
  • The company sold 500,000 Onco‑Innovations shares for a gain of $765,065.33, 346,050 ASEP Medical shares for a gain of $118,255.57, and 652,579 Core One Labs shares for a gain of $167,473.19.
  • Management highlighted the disciplined investment approach and reaffirmed focus on creating sustainable shareholder value.

Key Details

  • Onco‑Innovations Investment:
  • Initial investment of $31,175 in June 2025.

  • Sold 500,000 shares in 2025, generating realized gains of $765,065.33.

  • ASEP Medical Holdings Investment:

  • Acquired 500,000 Safecoat Medical shares on 14 Nov 2022 at $0.0231 per share.
  • Received 461,400 ASEP shares (deemed value $0.20 per share) in exchange for Safecoat shares.

  • Sold 346,050 ASEP shares in 2025, generating realized gains of $118,255.57.

  • Core One Labs Investment:

  • Invested $200,000 on 8 Dec 2022 to acquire 16,186 shares of 1254571 B.C. Ltd. at $12.36 per share.
  • Shares converted into 527,961 Core One Labs (COOL) shares at $0.38 per share; received additional 131,990 bonus shares from milestones under a separate agreement.

  • Sold 652,579 COOL shares in 2025, generating realized proceeds of $348,068.19 and realized gains of $167,473.19.

  • Total Realized Gains for 2025: $1,050,793.69 across the three portfolio holdings.

  • CEO Comment: Kristian Thorlund stated the gains “reflect the thoughtful approach we take in selecting opportunities and supporting companies pursuing meaningful advancements” and reaffirmed a disciplined capital deployment strategy.

Notable Quotes

"We are pleased with the realized gains generated through our portfolio activities. These outcomes reflect the thoughtful approach we take in selecting opportunities and supporting companies pursuing meaningful advancements." – Kristian Thorlund, CEO

Read the original news release →

More from ONCO-INNOVATIONS LIMITED

Jun 30, 2026 · 19:00

Preclinical-stage PNKP inhibitor developer pivots to performance-based financing amid liquidity constraints.

Financings Jun 30, 2026 · 18:00

Onco-Innovations Initiates Polymer Process Development and Characterization Program for ONC010

M&A / Property Jun 26, 2026 · 18:00

Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010

Other Jun 26, 2026 · 08:30

Canadian preclinical-stage oncology company developing PNKP inhibitor ONC010 and AI-driven SynoGraph platform.

Other Jun 25, 2026 · 08:30

Preclinical PNKP inhibitor developer burns cash and raises capital while marketing AI oncology partnerships to a niche market.

Other Jun 23, 2026 · 18:00

Preclinical Oncology Developer Secures Polymer Partner to De-Risk ONC010 Manufacturing Ahead of IND Filing

M&A / Property